公开(公告)号：US20240307618A1

公开(公告)日：2024-09-19

申请号：US18675900

申请日：2024-05-28

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2205/52 ,  A61M2230/201

Abstract: Exemplary embodiments provide an approach to predicting meal and/or exercise events for an insulin delivery system that otherwise does not otherwise identify such events. The insulin delivery system may use a model of glucose insulin interactions that projects estimated future glucose values based on the history of glucose values and insulin deliveries for the user. The predictions of meal events and/or exercise events may be based on residuals between actual glucose values and predicted glucose values. The exemplary embodiments may calculate a rate of change of the residuals over a period of time and compare the rate of change to thresholds to determine whether there likely has been a meal event or an exercise event. The insulin delivery system may then take measures to account for the meal or exercise by the user.

公开(公告)号：US20240252753A1

公开(公告)日：2024-08-01

申请号：US18633816

申请日：2024-04-12

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Steven CARDINALI ,  Jason O'CONNOR ,  Eric BENJAMIN ,  Ian MCLAUGHLIN ,  David NAZZARO ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142 ,  G01N33/49 ,  G16H10/60 ,  G16H20/17 ,  G16H20/60 ,  G16H40/40 ,  G16H40/67 ,  G16H50/30 ,  G16H50/70

CPC classification number: A61M5/1723 ,  A61M5/14248 ,  G01N33/49 ,  G16H10/60 ,  G16H20/17 ,  G16H20/60 ,  G16H40/40 ,  G16H40/67 ,  G16H50/30 ,  G16H50/70 ,  A61M2005/1726 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.

公开(公告)号：US20240252751A1

公开(公告)日：2024-08-01

申请号：US18629121

申请日：2024-04-08

Applicant: INSULET CORPORATION

Inventor： Jason O’CONNOR ,  Joon Bok LEE ,  Trang LY ,  Todd VIENNEAU ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61K38/28 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61K38/28 ,  A61M5/14248 ,  A61M2005/14252 ,  A61M2205/18 ,  A61M2205/3553 ,  A61M2205/3584 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201 ,  A61M2230/63

Abstract: A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.

公开(公告)号：US20240185980A1

公开(公告)日：2024-06-06

申请号：US18440058

申请日：2024-02-13

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Trang LY ,  Eric BENJAMIN

IPC: G16H20/17 ,  A61M5/172 ,  G16H40/67

CPC classification number: G16H20/17 ,  A61M5/1723 ,  G16H40/67 ,  A61M2205/18 ,  A61M2205/3584 ,  A61M2205/505 ,  A61M2230/201

Abstract: Disclosed are a device, a computer-readable medium, and techniques that provide an onboarding process and an adaptivity process for a drug delivery device. A processor executing an onboarding process determines whether a history of delivered insulin to a user meets certain sufficiency requirements. The onboarding process enables a processor to cause the drug delivery device to administer doses of insulin to a user according to an initial total daily insulin dose calculation that is determined based on the sufficiency of the insulin delivery history. The initial total daily insulin may be adapted according to the adaptivity process as new insulin delivery is collected. The insulin delivery history, when sufficient, may be used to set total daily insulin dosages that enable automated insulin delivery upon replacement of a drug delivery device. The adaptivity process may be implemented to modify an initial insulin delivery doses to provide adapted insulin delivery doses.

公开(公告)号：US20240157053A1

公开(公告)日：2024-05-16

申请号：US18498275

申请日：2023-10-31

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  John D’ARCO ,  Yibin ZHENG ,  Jason O’CONNOR ,  James CAUSEY ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/17

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  G16H20/17 ,  A61M2005/1401 ,  A61M2005/1726

Abstract: Invasive glucose sensors and noninvasive glucose sensors may be used in conjunction to improve glucose management for a user. The rate of change (ROC) of glucose levels from a noninvasive glucose sensor may be used rather than or in conjunction with a glucose level of the user from a CGM. A basal insulin delivery rate to the user may be adjusted responsive to the ROC glucose level data from the noninvasive sensor. The glucose level ROC from a noninvasive glucose sensor may be used to predict future glucose level ROCs of the user between operational cycles of an insulin delivery device and/or to identify possible hypoglycemic or hyperglycemic events. These predicted future glucose level ROCs may be used in a cost function of the control system of the insulin delivery device to select basal insulin delivery doses. Glucose level readings may be used to calibrate a noninvasive glucose level sensor.

公开(公告)号：US20240009392A1

公开(公告)日：2024-01-11

申请号：US18350223

申请日：2023-07-11

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Joshua WILLIAMS ,  Jason O'CONNOR ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2202/0486

Abstract: Exemplary embodiments may determine anticipated basal insulin delivery action to a user from an insulin delivery device over a future time window. Indications of the anticipated basal insulin delivery action over the future time window may be output to the user. The exemplary embodiments may determine the anticipated basal insulin delivery action over the future time window based on a rate of change (ROC) of glucose level of the user by the insulin delivery device, a most recent (“current”) glucose level for the user and insulin on board (IOB) for the user. The exemplary embodiments may also determine whether the user is likely to experience a undesired high glucose level (e.g., hyperglycemia) and/or an undesired low glucose level (e.g., hypoglycemia) during the future time window. The exemplary embodiments may output recommendations based on the projected glucose levels of the user over the future time window.

公开(公告)号：US20230402149A1

公开(公告)日：2023-12-14

申请号：US18199638

申请日：2023-05-19

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  William WHITELEY ,  Saeed SALAVATI ,  Yibin ZHENG ,  Mert SEVIL ,  Jason O’CONNOR

IPC: G16H20/17 ,  A61B5/145 ,  A61B5/00

CPC classification number: G16H20/17 ,  A61B5/7275 ,  A61B5/14532

Abstract: Exemplary embodiments may provide for the switching of glucose prediction models responsive to certain conditions. For example, glucose prediction models may be switched responsive to a detected crashing glucose level condition. Exemplary embodiments also may dynamically customize parameters, such as coefficient values, of the glucose prediction model to a user. The exemplary embodiments may customize the glucose prediction model based on the history of glucose levels of the user and the history of insulin deliveries to the user. The exemplary embodiments may determine a set of parameters that provides an improved fit of the parameters to the history of glucose levels and insulin deliveries of the user. The improved fit parameters may be used to adapt the parameter set to the most recent run.

公开(公告)号：US20230372613A1

公开(公告)日：2023-11-23

申请号：US18199476

申请日：2023-05-19

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2205/52

Abstract: The exemplary embodiments may employ a glucose prediction model (GPM) that is tailored to a user to account for insulin sensitivity or insulin insensitivity. The exemplary embodiments may predict future glucose levels based on past glucose levels for the user. Specifically, the GPM in exemplary embodiments may predict the future glucose level of the user as a weighted sum of most recent glucose level readings from the user. The exemplary embodiments may employ linear regression analysis to determine the values of the weights. These weights customize the GPM of the user based on the user's most recent glucose level history. Due to the customization, the GPM may more accurately predict future glucose levels of the user. As a result, the AID may exhibit better glucose level control for the user. The GPM of the exemplary embodiments may be updated on an ongoing basis.

公开(公告)号：US20230330337A1

公开(公告)日：2023-10-19

申请号：US18300201

申请日：2023-04-13

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Ashutosh ZADE ,  Jonathan HARDY

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2202/0486

Abstract: Disclosed herein are various embodiments comprising methods to propose or modify a basal profile of a user, wherein the basal profile is delivered by an automatic drug delivery system operating in manual mode or is administered manually by the user. Suggestions of initial basal profiles or modifications to existing basal profiles may be based on previous glucose control outcomes or previous insulin delivery as recorded by the automatic drug delivery system.

公开(公告)号：US20230285671A1

公开(公告)日：2023-09-14

申请号：US18119062

申请日：2023-03-08

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG ,  Jonathan HARDY

IPC: A61M5/172 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17 ,  A61M2230/201

Abstract: The exemplary embodiments provide an automated approach for adjusting the medicament delivery rate to the user when operating in an open loop manner (“open mode”). The approach relies upon an insulin delivery history to the user make adjustments to the medicament delivery rate in the open mode. In particular, the exemplary embodiments may look at the medicament delivery history while the medicament delivery device is operating in a closed loop manner (“closed mode”) to determine how to adjust the open mode medicament delivery rate. It is presumed that in closed mode, the control system of the medicament device has gained knowledge over time about how to control the medicament delivery rate to produce good treatment outcomes for the user. The exemplary embodiments leverage this knowledge to adjust the open mode medicament delivery rates. Medicament bolus deliveries in open mode may also be adjusted in like fashion.